Filtered By:
Drug: Donepezil
Education: Study
This page shows you your search results in order of date.
Order by Relevance | Date
Total 16 results found since Jan 2013.
The efficacy and safety of post-stroke cognitive impairment therapies: an umbrella review
Conclusion: Our study demonstrated that ACEI inhibitors (Donepezil) and NMDA antagonists (Memantine), EGB761, and acupuncture are the ADL and BI, MoCA, and neurological function deficit medication/therapy, respectively, for patients with PSCI.Clinical Trial Registration:https://inplasy.com/inplasy-2022-11-0139/; Identifier: INPLASY2022110139.
Source: Frontiers in Pharmacology - August 24, 2023 Category: Drugs & Pharmacology Source Type: research
FDA Approves Lecanemab, a New Alzheimer ’s Drug
On Jan. 6, the U.S. Food and Drug Administration (FDA) approved a new drug to treat Alzheimer’s disease in its early stages.
Lecanemab, which will be available under the name Leqembi, can slow the cognitive decline associated with Alzheimer’s disease by 27%, according to data submitted to the FDA by the drug’s developers, Eisai and Biogen. It’s only the second medication to show any improvement in neurodegeneration, a key criterion in the FDA’s consideration for approval.
“For a long time, this is what we have been looking for,” says Dr. Sam Gandy, professor of neurology and psychi...
Source: TIME: Health - January 6, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news
Donepezil alone and combined with intensive language-action therapy on depression and apathy in chronic post-stroke aphasia: A feasibility study
Brain Lang. 2022 Dec 7;236:105205. doi: 10.1016/j.bandl.2022.105205. Online ahead of print.NO ABSTRACTPMID:36495749 | DOI:10.1016/j.bandl.2022.105205
Source: Brain and Language - December 10, 2022 Category: Neurology Authors: Marcelo L Berthier Lisa Edelkraut Francisco J L ópez-González Diana L ópez-Barroso Bettina Mohr Friedemann Pulverm üller Sergio E Starkstein Ricardo E Jorge Mar ía José Torres-Prioris Guadalupe D ávila Source Type: research
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis
CONCLUSIONS: We found moderate- to high-certainty evidence that donepezil 5 mg, donepezil 10 mg, and galantamine have a slight beneficial effect on cognition in people with VCI, although the size of the change is unlikely to be clinically important. Donepezil 10 mg and galantamine 16 to 24 mg are probably associated with more adverse events than placebo. The evidence for rivastigmine was less certain. The data suggest that donepezil 10 mg has the greatest effect on cognition, but at the cost of adverse effects. The effect is modest, but in the absence of any other treatments, people living with VCI may still wish to consid...
Source: Cochrane Database of Systematic Reviews - March 11, 2021 Category: General Medicine Authors: Ceri E Battle Azmil H Abdul-Rahim Susan D Shenkin Jonathan Hewitt Terry J Quinn Source Type: research
Donepezil down-regulates propionylation, 2-hydroxyisobutyrylation, butyrylation, succinylation, and crotonylation in the brain of bilateral common carotid artery occlusion-induced vascular dementia rats.
In this study, we evaluated the effects of donepezil on VaD, and investigated the underlying molecular mechanisms of action. VaD was established by ligation of the bilateral common carotid artery occlusion (BCCAO). Executive function was tested by the Morris Water Maze (MWM) test and the attentional set shifting task (ASST). Our results showed that donepezil improved executive dysfunction and cognitive flexibility in BCCAO rats. In addition, we showed that donepezil treatment decreased the level of Aβ1-42 in BCCAO rats by enzyme-linked immunosorbent assay. Posttranslational modifications (PTMs) are known to be critical me...
Source: Clinical and Experimental Pharmacology and Physiology - May 17, 2020 Category: Drugs & Pharmacology Authors: Wang H, Lu J, Gao WC, Ma X, Li N, Ding Z, Wu C, Zhu M, Qiao G, Xiao C, Zhang C, Chen C, Weng Z, Yang W, Zheng CB Tags: Clin Exp Pharmacol Physiol Source Type: research
Donepezil improves gait performance in patients with an acute cerebral infarction: a prospective observational cohort study.
CONCLUSION: Admission NIHSS score, age and multiple sites infarction were independent risk factors of WGS score. Donepezil could improve gait performance in patients with an acute cerebral infarction.
PMID: 32282302 [PubMed - as supplied by publisher]
Source: Current Neurovascular Research - April 12, 2020 Category: Neurology Authors: Lin YY, Guo SJ, Quan H, Zhao YX, Huang DY Tags: Curr Neurovasc Res Source Type: research
Donepezil promotes neurogenesis via Src signaling pathway in a rat model of chronic cerebral hypoperfusion.
In this study, we investigated whether donepezil could promote SVZ neurogenesis in chronic cerebral hypoperfusion (CCH) injury via Src signaling pathway. In the bilateral carotid artery occlusion (2VO) rat model, we observed more nestin/5-bromo-2'-deoxyuridine (BrdU)-positive cells and doublecortin (DCX)/BrdU-positive cells in the SVZ than that in the sham group. Further, donepezil obviously improved neurologic function after 2VO, induced the greater number of SVZ proliferative NSCs and neuroblasts, and elevated levels of Src, p-FGFR1, p-EGFR, p-Akt and p-Raf in ipsilateral SVZ. Lastly, Src inhibitor KX-01 abolished the be...
Source: Brain Research - March 13, 2020 Category: Neurology Authors: Man J, Cui K, Fu X, Zhang D, Lu Z, Gao Y, Yu L, Li N, Wang J Tags: Brain Res Source Type: research
The efficacy and safety of pharmacological treatments for post-stroke aphasia.
Conclusions Current evidence suggests that drugs can improve the prognosis of post-stroke aphasia, such as donepezil, memantine. Donepezil has a significant effect in improving the ability of auditory comprehension, naming, repetition and oral expression. Memantine has a significant effect in improving the ability of naming, spontaneous speech and repetition. Bromocriptine showed no significant improvement in the treatment of aphasia after stroke. The trial for galantamine, amphetamine and levodopa in the treatment of aphasia after stroke is limited and inconclusive.
PMID: 29984673 [PubMed - as supplied by publisher]
Source: CNS and Neurological Disorders Drug Targets - July 6, 2018 Category: Drugs & Pharmacology Authors: Zhang X, Shu B, Zhang D, Huang L, Fu Q, Du G Tags: CNS Neurol Disord Drug Targets Source Type: research
ChAT-positive neurons participate in subventricular zone neurogenesis after middle cerebral artery occlusion in mice.
In this study, we assessed whether these ChAT(+) neurons also participate in stroke-induced neurogenesis. We used a permanent middle cerebral artery occlusion (MCAO) model produced by transcranial electrocoagulation in mice, atropine (muscarinic cholinergic receptor [mAchR] antagonist), and donepezil (acetylcholinesterase inhibitor) to investigate the role of ChAT(+) neurons in stroke-induced neurogenesis. We found that mAchRs, phosphorylated protein kinase C (p-PKC), and p-38 levels in the SVZ were upregulated in mice on day 7 after MCAO. MCAO also significantly increased the number of BrdU/doublecortin-positive cells and...
Source: Behavioural Brain Research - September 4, 2016 Category: Neurology Authors: Wang J, Fu X, Zhang D, Yu L, Li N, Lu Z, Gao Y, Wang M, Liu X, Zhou C, Han W, Yan B, Wang J Tags: Behav Brain Res Source Type: research
Neuroprotective effects of Danggui-Jakyak-San on rat stroke model through antioxidant/antiapoptotic pathway
Conclusion These suggest that DJ ameliorate the neurological dysfunction of cerebral ischemia through augmentation of antioxidant defense system and up-regulation of STAT3 and Pim-1. Graphical abstract
Source: Journal of Ethnopharmacology - May 16, 2016 Category: Drugs & Pharmacology Source Type: research
Probable Nootropic-induced Psychiatric Adverse Effects: A Series of Four Cases
Conclusion
Healthcare providers in general, and specifically those in the mental health and substance abuse fields, should keep in mind that nootropic use is an under recognized and evolving problem. Nootropic use should be considered in cases where there are sudden or unexplained exacerbations of psychiatric symptoms in patients who have been stable and medication adherent. It is also important to remember that most nootropics are not detected on standard drug toxicology screening tests.
We have very little clinical information on how nootropics may interact with psychotropics (or other medications) and potentially cause ...
Source: Innovations in Clinical Neuroscience - December 1, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Case Series and Literature Review Current Issue Mental Disorders Psychiatry Psychopharmacology Substance Use Disorders Ampakines Armodafinil brain enhancer Cerebrolysin Citicoline cognitive enhancer homeopathic medicine natural r Source Type: research
Amphetamine and other pharmacological agents in human and animal studies of recovery from stroke
Publication date: Available online 18 April 2015 Source:Progress in Neuro-Psychopharmacology and Biological Psychiatry Author(s): D. Walker-Batson , J. Mehta , P. Smith , M. Johnson Neuromodulation with pharmacological agents, including drugs of abuse such as amphetamine, when paired with behavioral experience, has been shown to positively modify outcomes in animal models of stroke. A number of clinical studies have tested the efficacy of a variety of drugs to enhance recovery of language deficit post-stroke. The purpose of this paper is to: (1) present pertinent animal studies supporting the use of dextro-amphetamine su...
Source: Progress in Neuro Psychopharmacology and Biological Psychiatry - April 28, 2015 Category: Psychiatry Source Type: research
Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation
ConclusionsA 2‐year follow‐up of patients receiving donepezil and NYT treatment showed an improved cognitive outcome and alleviation of AD‐related depression.
Source: Psychogeriatrics - April 27, 2015 Category: Geriatrics Authors: Chiaki Kudoh, Ryutaro Arita, Mitsuru Honda, Taichi Kishi, Yasuhiro Komatsu, Hiroaki Asou, Masaru Mimura Tags: Original Article Source Type: research
Bone Marrow-Derived Endothelial Progenitor Cells Protect Against Scopolamine-Induced Alzheimer-Like Pathological Aberrations
Abstract
Vascular endothelial dysfunction plays a key role in the pathogenesis of Alzheimer’s disease (AD). Patients with AD have displayed decreased circulating endothelial progenitor cells (EPCs) which repair and maintain the endothelial function. Transplantation of EPCs has emerged as a promising approach for the management of cerebrovascular diseases including ischemic stroke, however, its impact on AD has been poorly described. Thus, the current study aimed at investigating the effects of bone marrow-derived (BM) EPCs transplantation in repeated scopolamine-induced cognitive impairment, an experimental mode...
Source: Molecular Neurobiology - December 20, 2014 Category: Neurology Source Type: research
